{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:57:15Z","timestamp":1790881035988,"version":"4.1.0"},"reference-count":8,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj-2026-101000","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:05:17Z","timestamp":1790780717000},"page":"e101000","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["New Parkinson\u2019s drug approved in US\u2014but no clarity on when it might reach UK"],"prefix":"10.1136","volume":"394","author":[{"given":"Chris","family":"Baraniuk","sequence":"first","affiliation":[{"name":"Belfast"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"2026100110551251000_394.sep30_8.e101000.1","unstructured":"FDA Novel Drug Therapy Approvals for 2026. https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2026"},{"key":"2026100110551251000_394.sep30_8.e101000.2","unstructured":"Titheradge N. Drug warnings review after some patients \u2019misled\u2019 over impulsive behaviour side effects. https:\/\/www.bbc.co.uk\/news\/articles\/ckg0xxwn041o"},{"key":"2026100110551251000_394.sep30_8.e101000.3","unstructured":"Meglio M. NeuroVoices: Hubert Fernandez, MD, on Tavapadon, TEMPO-4, and Improving Parkinson Disease Management. https:\/\/www.neurologylive.com\/view\/neurovoices-hubert-fernandez-tavapadon-tempo-4-improving-parkinson-disease-management"},{"key":"2026100110551251000_394.sep30_8.e101000.4","unstructured":"Bezard E, Gray D, Kozak R, Leoni M, Combs C, and Duvvuri S. Rationale and Development of Tavapadon, a D1\/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson\u2019s Disease. https:\/\/www.eurekaselect.com\/article\/130629"},{"key":"2026100110551251000_394.sep30_8.e101000.5","unstructured":"Open-label Trial in Parkinson\u2019s Disease (PD) (TEMPO-4). https:\/\/clinicaltrials.gov\/study\/NCT04760769?term=tempo-4&intr=tavapadon&viewType=Card&rank=1"},{"key":"2026100110551251000_394.sep30_8.e101000.6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2026.0590"},{"key":"2026100110551251000_394.sep30_8.e101000.7","unstructured":"Fernandez H, Bhatia P, Cloud L, Fietzek U, Matarazzo M et al. Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson\u2019s disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial. https:\/\/www.thelancet.com\/journals\/laneur\/article\/PIIS1474-4422(26)00215-2\/abstract"},{"key":"2026100110551251000_394.sep30_8.e101000.8","unstructured":"Fernandez H, Isaacson S, Hauser R et al. Tavapadon as Adjunctive Treatment for Parkinson Disease. The TEMPO-3 Randomized Clinical Trial. https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2846847"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2026-101000","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2026-101000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:55:18Z","timestamp":1790877318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2026-101000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":8,"alternative-id":["10.1136\/bmj-2026-101000"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2026-101000","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}